GlassScriptPhysician profile
Geneva M Record
NPI 1003297078
$3,404.32
in general payments reported to CMS, 2019-2025
32 companies · $874 in 2025
The $874 reported for 2025 was more than what 95% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $703 · 2022: $406 · 2023: $645 · 2024: $776 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,280.85 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $695.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $375.00 | 2023-2025 | Gemtesa |
| Pfizer INC. | $319.02 | 2021-2025 | |
| Abbvie INC. | $251.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $241.46 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $221.43 | 2021-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $135.83 | 2021 | |
| Amgen INC. | $127.97 | 2021-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $124.99 | 2025 | Zoryve |
| Dexcom, INC. | $106.71 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $95.09 | 2021-2023 | Freestyle Libre 3 |
| Heartflow, INC. | $78.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $70.08 | 2023-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $53.57 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.90 | 2021-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $42.57 | 2025 | Gvoke Hypopen, Keveyis |
| Amarin Pharma, INC. | $42.32 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $39.58 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.13 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $34.32 | 2021-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $31.08 | 2021-2022 | |
| Inspire Medical Systems, INC. | $28.85 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $28.75 | 2021 | |
| Lundbeck LLC | $28.64 | 2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $23.97 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.50 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.14 | 2025 | Caplyta |
| Shield Therapeutics INC | $17.31 | 2022 | |
| Boston Scientific Corporation | $16.34 | 2021 | |
| Medtronic, INC. | $15.58 | 2023 | Intellis Adaptivestim |
| Daiichi Sankyo INC. | $14.49 | 2023 | Injectafer |
| Lilly USA, LLC | $13.80 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geneva Record listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.